Inhibition of bruton’s tyrosine kinase suppresses EL4 T cell lymphoma growth and alters key survival pathways 2762

Abstract Description Bruton’s tyrosine kinase (BTK) inhibitors hold promise as targeted therapies for lymphoma, a heterogeneous group of blood cancers often characterized by dysregulated receptor signaling. Despite their clinical potential, the specific effects of BTK inhibitors on T-cell lymphoma cell lines and the associated transcriptional changes remain underexplored. This study aimed to evaluate the efficacy of BTK inhibitors in reducing T-cell lymphoma cell proliferation and to identify transcriptional changes induced by the treatment. In vitro experiments were conducted on EL4 T-cell lymphoma cell lines, where cells were treated with varying concentrations of a selective BTK inhibitor. Proliferation was assessed using trypan blue exclusion counting, and gene expression levels of key target genes were quantified using quantitative PCR (qPCR). Key results showed that BTK inhibition significantly reduced proliferation in the EL4 cell line and, in some cases, led to complete growth arrest. qPCR analysis identified significant transcriptional gene changes associated with cell survival and apoptosis, indicating that BTK inhibition affects critical pathways involved in T-cell lymphoma progression. These findings support the therapeutic potential of BTK inhibitors in T-cell lymphomas and contribute to the growing evidence that BTK is a viable target for intervention. Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)